Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma

Abstract

This study developed a novel approach of targeting malignant glioma with pMAGE-A1_278–286-specific cytotoxic T lymphocytes (CTLs) induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with human leukocyte antigen (HLA)-A2-restricted pMAGE-A1_278–286 peptide-pulsed dentritic cells. Cytotoxic assays were performed by the colorimetric CytoTox 96 assay to analyze cytotoxic activity of the induced CTLs against various target cells. The induced CTLs showed approximately 45% specific lysis against T2pMAGE-A1_278–286 (pMAGE-A1_278–286 peptide pulsed T2 cells) and U251 (HLA-A2⁺, MAGE-A1⁺) at an effector:target ratio of 40:1, and approximately 5% cytolysis against T2pHIV, A172 (HLA-A2⁻, MAGE-A1⁺), K562 and T2 cells without being pulsed with peptide at any effector:target ratio. The specific killing activity of the induced CTLs against T2pMAGE-A1_278–286 and U251 was much more obvious than in any other control group (P<0.05). The cytotoxic activity against the T2pMAGE-A1_278–286 and U251 was significantly eliminated by anti-HLA class I mAb W6/32. These results suggest that pMAGE-A1_278–286 epitope may serve as a surrogate tumor antigen target of specific immunotherapy for treating HLA-A2 patients with malignant glioma.

Keywords

immunotherapy / glioma / MAGE-A1 / CTLs

References

[1] WenP.Y., KesariS.. Malignant gliomas. Curr Neurol Neurosci, 2004, 4(3): 218-227

[2] WalkerP.R., CalzasciaT., De TriboletN., et al.. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev, 2003, 42(2): 97-122

[3] PlautzG.E., MillerD.W., BarnetG.H., et al.. T Cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res, 2000, 6(6): 2209-2218

[4] HayesR.L., ArbitE., OdaimiM., et al.. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol, 2001, 39(1–2): 31-42

[5] AshleyD.M., FaiolaB., NairS., et al.. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med, 1997, 186(7): 1177-1182

[6] OkadaH., TaharaH., ShurinM.R., et al.. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer, 1998, 78(2): 196-201

[7] LiauL.M., BlackK.L., PrinsR.M., et al.. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg, 1999, 90(6): 1115-1124

[8] KobayashiT., YamanakaR., HommaJ., et al.. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother, 2003, 52(10): 632-637

[9] BanchereauJ., BriereF., CauxC., et al.. Immunobiology of dendritic cells. Annu Rev Immunol, 2000, 18(1): 767-811

[10] ChoH.I., KimH.J., OhS.T., et al.. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte by dendritic cells transduced with recombinant adenoviruses. Vaccine, 2003, 22(2): 224-236

[11] LambertL.A., GibsonG.R., MaloneyM., et al.. Intranodal immunization with tumor cell lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res, 2001, 61(1): 641-646

[12] NestleF.O., AlijagicS., GillietM., et al.. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998, 4(3): 328-332

[13] CandidoK.A., ShimizuK., McLaughlinJ.C., et al.. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res, 2001, 61(1): 228-236

[14] GodelaineD., CarrascoJ., LucasS., et al.. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3. A1 peptide. J Immunol, 2003, 171(9): 4893-4897

[15] CelluzziC.M., MayordomoJ.I., StorkusW.J., et al.. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 1996, 183(1): 283-287

[16] BoczkowskiD., NairS.K., SnyderD., et al.. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med, 1996, 184(2): 465-472

[17] ManickanE., KanangatS., RouseR.J., et al.. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukocyte Biol, 1997, 61(2): 125-132

[18] CondonC., WatkinsS.C., CelluzziC.M., et al.. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med, 1996, 2(10): 1122-1128

[19] TraversariC., van der BruggenP., LuescherI.F., et al.. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med, 1992, 176(5): 1453-1457

[20] van der BruggenP., SzikoraJ.P., BoëlP., et al.. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol, 1994, 24(9): 2134-2140

[21] GauglerB., Van den EyndeB., van der BruggenP., et al.. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med, 1994, 179(3): 921-930

[22] van der BruggenP., BastinJ., GajewskiT., et al.. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol, 1994, 24(12): 3038-3043

[23] HermanJ., van der BruggenP., LuescherI.F., et al.. Coulie PGA peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics, 1996, 43(6): 377-383

[24] OttavianiS., ZhangY., BoonT., et al.. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother, 2005, 54(12): 1214-1220

[25] ParkerK.C., BednarekM.A., HullL.K., et al.. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol, 1992, 149(11): 3580-3587

[26] AltmanJ.D., MossP.A., GoulderP.J., et al.. Phenotypic analysis of antigen-specific T lymphocytes. Science, 1996, 274(5284): 94-96

[27] MolldremJ.J., LeeP.P., WangC., et al.. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res, 1999, 59(11): 2675-2681

[28] ReesW., BenderJ., TeagueT.K., et al.. An inverse relationship between T cell receptor affinity and antigen dose during CD4+ T cell responses in vivo and in vitro. Proc Natl Acad Sci USA, 1999, 96(17): 9781-9786

[29] StuppR., MasonW.P., van den BentM.J., et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005, 10(10): 987-996

[30] RosenbergS.A., PackardB.S., AebersoldP.M., et al.. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, special report. N Engl J Med, 1988, 319(25): 1676-1680

[31] RimoldiD., RomeroP., CarrelS.. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer, 1993, 54(3): 527-528

[32] ChiD.D., MerchantR.E., RandR., et al.. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol, 1997, 150(6): 2143-2152

[33] ScarcellaD.L., ChowC.W., GonzalesM.F., et al.. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res, 1999, 5(2): 335-341

[34] SahinU., KoslowskiM., TüreciO., et al.. Expression of cancer testis genes in human brain tumors. Clin Cancer Res, 2000, 6(10): 3916-3922

[35] SchwechheimerK., LaufleR.M., SchmahlW., et al.. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol, 1994, 25(8): 772-780

[36] HiesigerE.M., HayesR.L., PierzD.M., et al.. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol, 1993, 16(2): 93-104

[37] PrinsR.M., OdesaS.K., LiauL.M.. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res, 2003, 63(23): 8487-8491

[38] LiuG., KhongH.T., WheelerC.J., et al.. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother, 2003, 26(4): 301-312

[39] DebinskiW., GiboD.M., HuletS.W., et al.. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res, 1999, 5(5): 985-990

[40] OkanoF., StorkusW.J., ChambersW.H., et al.. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res, 2002, 8(9): 2851-2855

[41] LuX.L., JiangX.B., LiuR.E., et al.. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells. Cancer Letters, 2007, 256(1): 128-135